Enhertu shows 14.3-month PFS in first-line lung cancer trial

September 13, 2026 9:45 PM

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) reported that their cancer drug Enhertu (trastuzumab deruxtecan) demonstrated a median ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found